EQ Equillium, Inc.
Financings ·
Equillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029.
Equillium reported a second-quarter net loss of $4.7 million and cash and cash equivalents of $57.2 million at June 30, 2026, which it says can fund planned operations into 2029.
Equillium said cash and cash equivalents were $61.3 million at March 31, 2026, following a $35 million private placement with RA Capital Management completed in March 2026.
Equillium's public float of about $93.7 million lifts it above Form S-3 sales limits. The company had sold $0.96 million of stock under the program so far, against the $21,950,000 covered by the earlier prospectus.
Nasdaq notified the company on August 29, 2025. Its shares closed at $1.00 or more for at least 10 consecutive business days.
Nasdaq extended Equillium's deadline to December 8, 2025. The company says it will consider options including a reverse stock split, and its stock keeps trading on the Nasdaq Capital Market as "EQ".
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $41.1 million | |
| Net income (loss) | -$22.4 million | -$8.1 million |
| Cash from operations | -$22.7 million | -$19.0 million |
| Cash and equivalents | $30.3 million | $18.1 million |
| Short-term investments | $4.5 million |
Our latest story on this, dated Jun 13, 2025: "Equillium gets 180 more days from Nasdaq to meet minimum bid price requirement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 26, 2026: "First EQ504 dosing unlocks a $20 million private placement tranche for Equillium". The story links the filing or release it is based on. Read the story.
Equillium, Inc. trades under the ticker EQ on NASDAQ.
Equillium, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0FY; LSE:0A4D.
The SEC Central Index Key (CIK) for Equillium, Inc. is 1746466. Its filings are on SEC EDGAR.
63,408,082 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Equillium, Inc. under United States.
Our directory classifies Equillium, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Equillium, Inc. is US29446K1060.
aibio.space lists Equillium, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Equillium, Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $22.7 million of cash in operations, per its annual report to the SEC.
$57.2 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Equillium, dated Oct 26, 2026: "First EQ504 dosing unlocks a $20 million private placement tranche for Equillium". Equillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029. Source.
From our story of Oct 26, 2026: The company says that with this closing its cash should fund planned operations into 2029. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio